Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated at Jefferies Financial Group

Analysts at Jefferies Financial Group started coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report issued to clients and investors on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Jefferies Financial Group’s price objective would indicate a potential upside of 66.17% from the stock’s previous close.

Several other research firms have also commented on ORKA. Guggenheim assumed coverage on Oruka Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $60.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, August 12th. HC Wainwright reduced their price target on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Barclays initiated coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They set an “overweight” rating and a $48.00 price target on the stock. Finally, Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.14.

Oruka Therapeutics Trading Up 2.7%

Shares of ORKA opened at $27.08 on Thursday. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $29.98. The firm has a market cap of $1.12 billion, a PE ratio of -9.64 and a beta of -0.30. The firm has a fifty day simple moving average of $22.60 and a two-hundred day simple moving average of $16.20.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.01. As a group, research analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Jefferies Financial Group Inc. boosted its stake in Oruka Therapeutics by 15.7% during the first quarter. Jefferies Financial Group Inc. now owns 405,029 shares of the company’s stock worth $4,156,000 after buying an additional 55,000 shares during the period. Candriam S.C.A. acquired a new position in shares of Oruka Therapeutics in the 1st quarter worth approximately $1,197,000. AlphaQuest LLC acquired a new stake in Oruka Therapeutics in the 1st quarter valued at approximately $168,000. Affinity Asset Advisors LLC increased its holdings in Oruka Therapeutics by 47.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock valued at $5,595,000 after purchasing an additional 176,664 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp increased its holdings in Oruka Therapeutics by 126.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock valued at $461,000 after purchasing an additional 25,100 shares during the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.